Product Description
Primidone is an aromatic anticonvulsant used to treat complex, partial, and generalized seizures. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK562297/)
Mechanisms of Action: GABA Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | China | Colombia | Czech | Estonia | France | Germany | Greece | Hungary | India | Ireland | Israel | Italy | Korea | Lithuania | Luxembourg | Malta | Mexico | Netherlands | New Zealand | Pakistan | Peru | Poland | Portugal | Russia | Slovenia | South Africa | Spain | Sri Lanka | Switzerland | Taiwan | Turkey | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|